Search results

...as [[lead compound|leads]] in the development of new [[pharmaceutical drug|therapeutic agents]]. Some can inhibit a specific function of a protein or disrupt [[pr ...oduct]]s). With the exception of [[Monoclonal antibody therapy|therapeutic antibodies]], many proteins are degraded if administered orally and most often cannot ...

...とがあるが、これは直接的な影響というよりも、グルコースの急激な低下によって間接的に引き起こされると考えられている。患者の中には[[anti-drug antibodies/ja|抗薬物抗体]]を発症する者がいるが、これは他のGLP-1作動薬よりも[[exenatide/ja|エキセナチド]]でよくみられ（抗薬物抗体は患者 ...る。これらの付加的な標的は、薬物によって引き起こされる体重減少の量を改善することが期待されている。グルカゴン作動薬との併用は，さらなるリスクと低い[[therapeutic index/ja|治療指数]]を犠牲にして，薬剤の減量効果をより高める可能性が高い。 ...

{{Short description|Antibodies from clones of the same blood cell}} ...elboin HV, Krausz KW, Gonzalez FJ, Yang TJ | title = Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery | journal ...

| -mab || [[Monoclonal antibodies]]<ref name=AMA/> || [[trastuzumab]], [[ipilimumab]] ...the likelihood of the patient developing their own antibodies against the therapeutic antibody) <ref name = AMA/> || [[infliximab]] ...

...rapies]], [[tissue (biology)|tissues]], [[recombinant proteins|recombinant therapeutic protein]], and [[living medicine]]s used in [[cell therapy]]. Biologics can ...egulatory agencies]] use the terms ''biological medicinal products'' or '''therapeutic biological product''' to refer specifically to engineered [[macromolecule|m ...

...r production, production process, purification process, formulation of the therapeutic protein into a drug. ...human [[growth hormone]], [[interferons]], [[erythropoietin]], monoclonal antibodies and more) any other biotech company can develop and market these [[biologic ...

...r production, production process, purification process, formulation of the therapeutic protein into a drug. ...human [[growth hormone]], [[interferons]], [[erythropoietin]], monoclonal antibodies and more) any other biotech company can develop and market these [[biologic ...

...op [[anti-drug antibodies]], which are more common with [[exenatide]] (the antibodies were detectable in a third or more of patients) than other GLP-1 agonists a ...ficacious for weight loss, at the expense of additional risk and a lower [[therapeutic index]]. ...

...op [[anti-drug antibodies]], which are more common with [[exenatide]] (the antibodies were detectable in a third or more of patients) than other GLP-1 agonists a ...ficacious for weight loss, at the expense of additional risk and a lower [[therapeutic index]]. ...

'''Immunoglobulin therapy''' is the use of a mixture of [[antibodies]] ('''normal human immunoglobulin''' or '''NHIG''') to treat several health ...bulin is made from human [[blood plasma]].<ref name=AHFS2017/> It contains antibodies against many [[viruses]].<ref name=BNF69/> ...

...する必要がある。このような薬物相互作用は、患者にとって極めて重要な薬物、重大な[[adverse effect/ja|副作用]]を伴う薬物、または[[therapeutic index/ja|治療指数]]の狭い薬物を使用する場合に特に考慮する必要があるが、どのような薬物でも薬物代謝の変化により血漿中濃度が変化する可能性があ CYP3A4の基質の多くは、[[amiodarone/ja|アミオダロン]]や[[carbamazepine/ja|カルバマゼピン]]などの[[therapeutic index/ja|治療指数]]が狭い薬物である。これらの薬物はCYP3A4によって代謝されるため、これらの薬物の[[mean plasma level ...

...替医療として使用されており、消化されると[[Broad-spectrum therapeutic/ja|広範囲の免疫活性]]を顕著に刺激し、特定の[[antibodies/ja|抗体]]（[[IgM/ja|IgM]]、[[Immunoglobulin G/ja|IgG]]、[[IgA/ja|IgA]]）の分泌の活性化や[ ...

...is the [[Anatomical Therapeutic Chemical Classification System|Anatomical Therapeutic Chemical Classification System]]. The [[:en:World Health Organization|World ...is the [[Anatomical Therapeutic Chemical Classification System|Anatomical Therapeutic Chemical Classification System]] (ATC system). The [[World Health Organizat ...

...d via subcutaneous injection or infusion include [[insulin]], [[monoclonal antibodies]], and [[heparin]]. These medications cannot be administered orally as the ...-list-style = vanc | doi-access = free }}</ref> as well as many monoclonal antibodies. In most cases, injection site reactions are self-limiting and resolve on t ...

...is the [[Anatomical Therapeutic Chemical Classification System|Anatomical Therapeutic Chemical Classification System]]. The [[:en:World Health Organization|World ...is the [[Anatomical Therapeutic Chemical Classification System|Anatomical Therapeutic Chemical Classification System]] (ATC system). The [[World Health Organizat ...

...with significant [[adverse effect|side-effects]], or drugs with a narrow [[therapeutic index]], but any drug may be subject to an altered plasma concentration due Many substrates for CYP3A4 are drugs with a narrow [[therapeutic index]], such as [[amiodarone]] or [[carbamazepine]]. Because these drugs a ...

...houghts and feelings go a long way in therapy recovery, this is called the therapeutic process.<ref>{{Cite web |date=2020-07-20 |title=Psychotherapy: What to expe ****** by [[monoclonal antibody|monoclonal antibodies]]: [[monoclonal antibody therapy]] ...

...with significant [[adverse effect|side-effects]], or drugs with a narrow [[therapeutic index]], but any drug may be subject to an altered plasma concentration due Many substrates for CYP3A4 are drugs with a narrow [[therapeutic index]], such as [[amiodarone]] or [[carbamazepine]]. Because these drugs a ...

...l growth and development. Before recombinant HGH became available, HGH for therapeutic use was obtained from pituitary glands of cadavers. This unsafe practice le ...gy |url=https://www.evitria.com/journal/recombinant-antibodies/recombinant-antibodies-next-level-antibody-technology/ |url-status=live}}</ref> ...

...spectrum immune activity]] including activation of secretion of specific [[antibodies]] [[IgM]], [[Immunoglobulin G|IgG]] and [[IgA]] and release of [[CpG dinucl ...